Israel Englander Macrogenics Inc Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Macrogenics Inc stock. As of the latest transaction made, Millennium Management LLC holds 3,312,672 shares of MGNX stock, worth $13.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,312,672

Previous 92,695 3473.73%

Holding current value

$13.9 Million

Previous $1.36 Million 932.11%

% of portfolio

0.01%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.31 - $18.51 $10.7 Million - $59.6 Million	3,219,977 Added 3473.73%	3,312,672 $14.1 Million
Q1 2024 May 15, 2024	SELL	$9.77 - $21.47 $7.53 Million - $16.5 Million	-770,270 Reduced 89.26%	92,695 $1.36 Million
Q4 2023 Feb 14, 2024	SELL	$4.48 - $10.11 $679,096 - $1.53 Million	-151,584 Reduced 14.94%	862,965 $8.3 Million
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $4.34 Million - $7.09 Million	-939,801 Reduced 48.09%	1,014,549 $5.43 Million
Q1 2023 May 15, 2023	SELL	$4.82 - $7.24 $4.11 Million - $6.17 Million	-852,885 Reduced 30.38%	1,954,350 $14 Million
Q4 2022 Feb 14, 2023	SELL	$3.34 - $6.98 $2.45 Million - $5.13 Million	-734,717 Reduced 20.74%	2,807,235 $18.8 Million
Q3 2022 Nov 14, 2022	BUY	$3.01 - $5.22 $2.81 Million - $4.87 Million	932,390 Added 35.73%	3,541,952 $12.3 Million
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $2.46 Million - $10.9 Million	1,091,427 Added 71.89%	2,609,562 $7.7 Million
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $3.97 Million - $8.26 Million	488,599 Added 47.46%	1,518,135 $13.4 Million
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $8.23 Million - $11.3 Million	517,487 Added 101.06%	1,029,536 $16.5 Million
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $586,672 - $852,964	29,720 Added 6.16%	512,049 $10.7 Million
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $1.22 Million - $2.12 Million	59,627 Added 14.11%	482,329 $13 Million
Q1 2021 May 17, 2021	SELL	$18.99 - $33.2 $3 Million - $5.24 Million	-157,878 Reduced 27.19%	422,702 $13.5 Million
Q4 2020 Feb 16, 2021	SELL	$19.41 - $26.0 $1.76 Million - $2.36 Million	-90,746 Reduced 13.52%	580,580 $13.3 Million
Q3 2020 Nov 16, 2020	SELL	$24.69 - $31.6 $12.6 Million - $16.2 Million	-511,495 Reduced 43.24%	671,326 $16.9 Million
Q2 2020 Aug 14, 2020	SELL	$5.2 - $29.12 $2.32 Million - $13 Million	-446,198 Reduced 27.39%	1,182,821 $33 Million
Q1 2020 May 14, 2020	SELL	$4.28 - $12.11 $2.94 Million - $8.31 Million	-685,812 Reduced 29.63%	1,629,019 $9.48 Million
Q4 2019 Feb 14, 2020	SELL	$7.95 - $12.27 $6.59 Million - $10.2 Million	-829,086 Reduced 26.37%	2,314,831 $25.2 Million
Q3 2019 Nov 14, 2019	BUY	$12.44 - $17.48 $2.46 Million - $3.46 Million	197,867 Added 6.72%	3,143,917 $40.1 Million
Q2 2019 Aug 14, 2019	BUY	$14.51 - $19.71 $20.7 Million - $28.1 Million	1,423,910 Added 93.55%	2,946,050 $50 Million
Q1 2019 May 14, 2019	BUY	$11.11 - $25.6 $14 Million - $32.4 Million	1,264,460 Added 490.71%	1,522,140 $27.4 Million
Q4 2018 Feb 14, 2019	BUY	$11.75 - $21.42 $359,808 - $655,923	30,622 Added 13.49%	257,680 $3.27 Million
Q3 2018 Nov 14, 2018	SELL	$19.26 - $23.46 $3.82 Million - $4.65 Million	-198,241 Reduced 46.61%	227,058 $4.87 Million
Q2 2018 Aug 14, 2018	SELL	$19.78 - $24.67 $9.35 Million - $11.7 Million	-472,683 Reduced 52.64%	425,299 $8.78 Million
Q1 2018 May 15, 2018	BUY	$18.89 - $32.46 $7.85 Million - $13.5 Million	415,681 Added 86.19%	897,982 $22.6 Million
Q4 2017 Feb 14, 2018	BUY	$16.19 - $20.3 $6.72 Million - $8.43 Million	415,262 Added 619.43%	482,301 $9.16 Million
Q3 2017 Nov 14, 2017	BUY	$15.52 - $18.94 $1.04 Million - $1.27 Million	67,039	67,039 $1.24 Million

Others Institutions Holding MGNX

# of Institutions

150

Shares Held

60.4M

Call Options Held

218K

Put Options Held

259K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $258M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account